Search

Author/Creator Mourah, S.

11. Ifosfamide and etoposide in advanced‐stage, relapsed or refractory primary cutaneous T‐cell lymphomas. (1st November 2020)

Authors:
Dangien, A.; Ram‐Wolff, C.; Brice, P.; Battistella, M.; Roelens, M.; Moins‐Teisserenc, H.; Peffault de Latour, R.; Mourah, S.; Bouaziz, J.‐D.; Lebbé, C.; Bagot, M.; de Masson, A.
Journal:
British journal of dermatology
Issue:
Volume 183:Number 5(2020)
Page Start:
961
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

12. Image‐guided lymph node core‐needle biopsy predicts survival in mycosis fungoides and Sézary syndrome. (1st August 2021)

Authors:
Calvani, J.; de Masson, A.; de Margerie‐Mellon, C.; de Kerviler, É.; Ram‐Wolff, C.; Gruber, A.; Meignin, V.; Brice, P.; Sadoux, A.; Mourah, S.; Bagot, M.; Battistella, M.
Journal:
British journal of dermatology
Issue:
Volume 185:Number 2(2021)
Page Start:
419
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

13. Image‐guided lymph node core‐needle biopsy predicts survival in mycosis fungoides and Sézary syndrome. (1st March 2021)

Authors:
Calvani, J.; de Masson, A.; de Margerie‐Mellon, C.; de Kerviler, É.; Ram‐Wolff, C.; Gruber, A.; Meignin, V.; Brice, P.; Sadoux, A.; Mourah, S.; Bagot, M.; Battistella, M.
Journal:
British journal of dermatology
Issue:
Volume 185:Number 2(2021)
Page Start:
419
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

14. Malignant, benign conventional and regulatory T immune compartments in 36 patients treated with mogamulizumab for advanced CTCL. (2019)

Authors:
Roelens, M.; de Masson, A.; Battistella, M.; Mourah, S.; Estevez, M.J.; Delyon, J.; Herms, F.; Ram-Wolff, C.; Lebbé, C.; Bagot, M.; Moins-Teisserenc, H.
Journal:
European journal of cancer
Issue:
Volume 119(2019)Supplement 1
Page Start:
S4
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

15. Paradoxical simultaneous regression and progression of lesions in a phase II study of everolimus in classic Kaposi sarcoma. (19th August 2015)

Authors:
Mourah, S.; Porcher, R.; Battistella, M.; Kerob, D.; Guillot, B.; Jouary, T.; Agbalika, F.; Morinet, F.; Furlan, V.; Teisserenc, H.M.; Dupin, N.; Lebbé, C.
Journal:
British journal of dermatology
Issue:
Volume 173:Number 5(2015:Nov.)
Page Start:
1284
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

16. Paradoxical simultaneous regression and progression of lesions in a phase II study of everolimus in classic Kaposi sarcoma. (1st November 2015)

Authors:
Mourah, S.; Porcher, R.; Battistella, M.; Kerob, D.; Guillot, B.; Jouary, T.; Agbalika, F.; Morinet, F.; Furlan, V.; Teisserenc, H.M.; Dupin, N.; Lebbé, C.
Journal:
British journal of dermatology
Issue:
Volume 173:Number 5(2015:Nov.)
Page Start:
1284
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

17. Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation. (15th July 2019)

Authors:
Ighilahriz, M.; Benfodda, M.; Sharpe, H.; Soufir, N.; Mourah, S.; Dumaz, N.; Battistella, M.; Savina, A.; Bouquet, F.; Nikolaev, S.; Basset‐Seguin, N.
Journal:
Journal of the European Academy of Dermatology and Venereology
Issue:
Volume 33:Number 11(2019)
Page Start:
e422
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗